Bioasis and Chiesi announce licensing agreement
Bioasis Technologies and Chiesi Global Rare Diseases have entered into a worldwide, exclusive licensing agreement re the Bioasis platform technology, with a focus on four...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Bioasis Technologies and Chiesi Global Rare Diseases have entered into a worldwide, exclusive licensing agreement re the Bioasis platform technology, with a focus on four...
Alexion Pharmaceuticals reports that the European Commission has approved ULTOMIRIS® (ravulizumab) — for certain adults and children with atypical hemolytic uremic syndrome (aHUS) … more Separately, Alexion...
BioCT is pleased to welcome Erika Smith to the Board of Directors. Erika is the CEO of ReNetX Bio, a clinical stage, venture funded company in...
The Jackson Laboratory (JAX) reports that the National Cancer Institute has renewed JAX’s prestigious Cancer Center Support Grant for the 34th year. As one of...
Tangen Biosciences has been awarded a contract to develop a point-of-care device for detection of Candida auris, a “superbug” that is resistant to anti-fungal drugs and...
A Yale University spin-off announced $25 million in new funding Wednesday, with plans to design proteins that would defeat “decoy” cells in the body that...
University of Connecticut researcher Dr. George Wu recently published a paper outlining his successful experiment delivering mitochondria to liver cells. This marks the first time researchers...
SpringWorks Therapeutics reports that the first patient has been dosed in a Phase 1b clinical trial evaluating the company’s investigational gamma secretase inhibitor, nirogacestat, in combination with...
Millions of patients around the world are suffering from the dramatic effects of fibrotic diseases. Whether the damage occurs in the liver, as in non-alcoholic...
Federal regulators have green-lighted Guilford’s AI Therapeutics to begin a clinical trial to test if its experimental drug for non-Hodgkin lymphoma and ALS could also...